167 related articles for article (PubMed ID: 31986424)
1. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series.
Signoriello E; Bonavita S; Sinisi L; Russo CV; Maniscalco GT; Casertano S; Saccà F; Lanzillo R; Morra VB; Lus G
Mult Scler Relat Disord; 2020 May; 40():101963. PubMed ID: 31986424
[TBL] [Abstract][Full Text] [Related]
2. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
[TBL] [Abstract][Full Text] [Related]
3. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
Aramideh Khouy R; Karampoor S; Keyvani H; Bokharaei-Salim F; Monavari SH; Taghinezhad S; Etemadifar M; Esghaei M
J Neuroimmunol; 2019 Mar; 328():94-97. PubMed ID: 30610966
[TBL] [Abstract][Full Text] [Related]
4. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
[TBL] [Abstract][Full Text] [Related]
5. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
[TBL] [Abstract][Full Text] [Related]
7. Herpes zoster laryngitis in a patient treated with fingolimod.
Hagiya H; Yoshida H; Shimizu M; Motooka D; Nakamura S; Iida T; Yamamoto N; Akeda Y; Tomono K
J Infect Chemother; 2016 Dec; 22(12):830-832. PubMed ID: 27553068
[TBL] [Abstract][Full Text] [Related]
8. Varicella vaccination after fingolimod: A case report.
Berger JR
Mult Scler Relat Disord; 2013 Oct; 2(4):391-4. PubMed ID: 25877852
[TBL] [Abstract][Full Text] [Related]
9. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.
Manouchehrinia A; Tanasescu R; Kareem H; Jerca OP; Jabeen F; Shafei R; Breuer J; Neal K; Irving W; Constantinescu CS
J Neurovirol; 2017 Dec; 23(6):839-844. PubMed ID: 28895088
[TBL] [Abstract][Full Text] [Related]
11. Serological and T Cell Responses After Varicella Zoster Virus Vaccination in HIV-Positive Patients Undergoing Renal Dialysis.
Righi E; Carnelutti A; La Rosa A; Sartor A; Tulissi P; Gallo T; Ivaldi F; Bassetti M
Viral Immunol; 2019 Apr; 32(3):151-157. PubMed ID: 30694731
[TBL] [Abstract][Full Text] [Related]
12. Varicella immunity: persistent serologic non-response to immunization.
Katial RK; Ratto-Kim S; Sitz KV; Moriarity R; Engler RJ
Ann Allergy Asthma Immunol; 1999 May; 82(5):431-4. PubMed ID: 10353572
[TBL] [Abstract][Full Text] [Related]
13. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular response after varicella vaccination in VZV IgG seronegative kidney transplant candidates.
Kho MM; Zuijderwijk JM; van der Eijk AA; de Kuiper R; Boer-Verschragen MJ; Weimar W; van Besouw NM
Vaccine; 2017 Jan; 35(1):71-76. PubMed ID: 27899225
[TBL] [Abstract][Full Text] [Related]
15. Reduced varicella-zoster-virus (VZV)-specific lymphocytes and IgG antibody avidity in solid organ transplant recipients.
Prelog M; Schönlaub J; Jeller V; Almanzar G; Höfner K; Gruber S; Eiwegger T; Würzner R
Vaccine; 2013 May; 31(20):2420-6. PubMed ID: 23583889
[TBL] [Abstract][Full Text] [Related]
16. [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
Winkelmann A; Löbermann M; Reisinger EC; Zettl UK
Nervenarzt; 2012 Feb; 83(2):236-42. PubMed ID: 21845450
[TBL] [Abstract][Full Text] [Related]
17. Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults.
van der Heiden M; de Rond LGH; van Zelm MC; Berbers GAM; Boots AMH; Buisman AM
Front Immunol; 2018; 9():46. PubMed ID: 29410671
[TBL] [Abstract][Full Text] [Related]
18. Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list.
Speth F; Hinze CH; Andel S; Mertens T; Haas JP
Pediatr Rheumatol Online J; 2018 Mar; 16(1):15. PubMed ID: 29499726
[TBL] [Abstract][Full Text] [Related]
19. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
